|
Patent landscape, scope, and claims: |
Overview of US Patent 8,268,847: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 8,268,847, granted on September 18, 2012, to the University of Michigan, pertains to novel compounds, compositions, and methods for treating various medical conditions using selective inhibitors of phosphodiesterase 4 (PDE4). The patent's scope primarily covers a class of compounds that exhibit therapeutic activity against inflammation, neurodegenerative diseases, and other disorders. This detailed analysis explores the patent’s claims, scope, and its position within the broader pharmaceutical patent landscape, including potential competitors, related patents, and landscape dynamics.
What is the Scope of U.S. Patent 8,268,847?
Primary Focus
The patent broadly claims chemical entities, methods for their synthesis, and therapeutic applications, especially their use as PDE4 inhibitors. PDE4 inhibitors are recognized for their anti-inflammatory, immunomodulatory, and neuroprotective properties.
Chemical Coverage
- The patent encompasses heterocyclic compounds with particular structural features, such as pyrrolidine, piperidine, or related rings.
- It particularly emphasizes compounds with substituents that enhance selectivity and potency for PDE4.
- The claims include specific substitutions, stereochemistry, and salts associated with the core compounds.
Therapeutic Applications Covered
- Treatment of inflammatory disorders (e.g., COPD, asthma)
- Neurodegenerative diseases (e.g., Parkinson’s, Alzheimer’s)
- Psychiatric conditions (e.g., depression, anxiety)
- Other diseases involving immune modulation or inflammation
Claim Types and Hierarchy
- Independent claims describe the chemical compounds themselves.
- Dependent claims specify particular embodiments, such as specific substitutions, salts, formulations, or administration routes.
- Method claims cover methods of synthesizing the compounds and their therapeutic use.
Detailed Analysis of Patent Claims
Claim Breakdown
| Claim Number |
Type |
Scope and Key Features |
Implication |
| Claim 1 |
Independent |
Defines a chemical compound with specific heterocyclic structures and substitutions. |
Core chemical entity, foundational to the patent's scope. |
| Claims 2–10 |
Dependent |
Narrow variations of Claim 1, including specific substituents or stereochemistry. |
Refinements and preferred embodiments, restricting freedom to operate. |
| Claims 11–15 |
Method claims |
Describe synthesis protocols and use of compounds in treating diseases. |
Establishs patentability over methods and therapeutic applications. |
| Claims 16–20 |
Formulation claims |
Claims related to pharmaceutical compositions comprising the compounds. |
Protects formulations, including dosage forms and delivery mechanisms. |
Key Claim Highlights
- Emphasizes a class of benzimidazole and related heterocyclic compounds, with specific R-group substitutions.
- Claims pharmaceutical compositions comprising these compounds, with optional excipients.
- Encompasses methods of treating inflammatory and neurodegenerative conditions via administration of the compounds.
Potential Limitations in Claims
- The scope hinges upon the novelty of specific substitutions; known heterocycles with similar features might challenge patent validity.
- Patent’s lifespan is limited as it expires on September 18, 2030, but patent term extensions or new patents could extend market exclusivity.
Patent Landscape and Market Context
Related Patents and Patent Families
- The patent family includes filings in Europe (EP 2,622,834) and Japan, emphasizing international protection.
- Several other patents filed by AbbVie (formerly Abbott), Cephalon, and Lilly also target PDE4 inhibitors, creating a dense patent landscape.
Major Competitors and Patent Holders
| Company/Institution |
Notable Patents |
Key Compounds |
Market Position |
| University of Michigan |
US 8,268,847 |
Specific heterocyclic PDE4 inhibitors |
Core patent for initial invention |
| Abbott/AbbVie |
Multiple patents covering Rolipram, Apremilast |
PDE4 inhibitors for psoriasis, arthritis |
Commercialized PDE4 drugs |
| GlaxoSmithKline |
Several patents |
Apremilast (Otezla) |
Approved PDE4 inhibitor for psoriasis and psoriatic arthritis |
| Clearside Biomedical |
Patents on ocular PDE4 inhibitors |
Eye disease treatments |
Niche markets |
Patent Filing Trends (2010–2023)
- Increased filings around heterocyclic PDE4 inhibitors targeting inflammatory and neurodegenerative diseases.
- Legal battles over claim scope and patent validity, especially with Salts and derivatives.
Comparison with Leading PDE4 Inhibitor Patents
| Aspect |
US 8,268,847 |
AbbVie’s U.S. Patent 8,221,714 |
GSK’s Patent covering Apremilast |
| Core compound class |
Heterocyclic PDE4 inhibitors |
Pyrazolopyridine derivatives |
Phthalazinone derivatives |
| Therapeutic focus |
Inflammation, neurodegeneration |
Psoriasis, COPD |
Psoriasis, psoriatic arthritis |
| Claim scope |
Broad heterocyclic class |
Specific molecules |
Specific formulations and indications |
| Market(s) |
Limited, pending approvals |
Approved drugs |
Approved drugs with broader claims |
Strategic Implications for Stakeholders
For Innovators
- The broad chemical claims create barriers for generic competitors, especially for companies developing heterocyclic PDE4 inhibitors.
- Focus on novel substitutions or mechanisms not covered explicitly within the patent scope.
For Generic Manufacturers
- Must analyze claim language intensively to avoid infringement.
- Strategies include designing compounds outside the scope of patent claims, such as alternative chemical classes.
For Patent Holders
- Maintain patent families in key jurisdictions, monitor claim enforcement and litigation risks.
- Consider continuation applications to extend claims into new chemical space or indications.
Deep Dive into the Patent Landscape
Temporal Context
| Year of Filing/Grant |
Key Developments |
| Filing (approx. 2008–2010) |
Rising interest in PDE4 inhibitors for neurological diseases. |
| Grant Date |
2012 |
First wide-reaching patents issued. |
| Recent Patent Filings |
2015–2023 |
Focus on combination therapies, novel delivery systems. |
Patent Challenges & Litigation
- Validity challenges based on prior art, particularly documented heterocyclic compounds.
- Infringement suits involve pharmaceutical companies and biotech firms wanting to develop PDE4 inhibitors.
Patent Expiry & Lifecycle
- Expected expiration in September 2030, but patent extensions or ancillary patents may prolong market exclusivity.
- Patent portfolios around the core compound may include composition-of-matter, method, and use patents, complicating generic entry.
Conclusion: The Patent Landscape for PDE4 Inhibitors and 8,268,847
- US 8,268,847 provides a substantial legal barrier through broad chemical claims and method protections.
- It sits within a competitive landscape characterized by numerous patents from major pharmaceutical players, emphasizing ongoing innovation.
- Strategic positioning involves considering scope limitations, closely monitoring related patents, and exploring novel chemical or therapeutic pathways.
Key Takeaways
- Scope: US 8,268,847 broadly claims heterocyclic PDE4 inhibitors with therapeutic use in inflammatory and neurodegenerative diseases.
- Claims: Cover both the compounds and methods of use, with specific substitutions and formulations detailed.
- Landscape: Dense with patents from industry leaders like AbbVie and GSK, posing significant innovation and litigation considerations.
- Strategies: Innovators should focus on structural novelty, while generics must navigate precise claim language.
- Future Outlook: Patent expiration around 2030, with potential extensions or new patent filings shaping the competitive period.
FAQs
Q1: How broad is the chemical scope of US 8,268,847?
A1: It covers a wide class of heterocyclic compounds with specific structural features, primarily targeting PDE4 inhibitors, including various substitutions, stereochemistry, and salts.
Q2: Does the patent protect only the compounds or also their therapeutic methods?
A2: Both. The patent claims include the chemical compounds, pharmaceutical compositions, and methods of treating relevant diseases using these compounds.
Q3: How does this patent interact with other PDE4 inhibitor patents?
A3: It overlaps with patents from major companies like AbbVie and GSK, though its broad chemical claims may create blocking effects but also face validity challenges.
Q4: When does the patent expire, and what implications does this have?
A4: The patent expires on September 18, 2030, potentially opening the market for generic development afterward, unless extended or complemented by new patents.
Q5: Can a competitor design around this patent?
A5: Yes, by developing inhibitors outside the claimed chemical scope, such as other heterocyclic classes or non-heterocyclic structures, provided they do not infringe existing claims.
References
- US Patent 8,268,847, "PDE4 Inhibitors," issued to University of Michigan, 2012.
- European Patent EP 2,622,834, "Heterocyclic PDE4 inhibitors," filed by University of Michigan.
- Abbott’s US Patent 8,221,714, "Pyrazolopyridine PDE4 inhibitors," 2012.
- GSK’s patent portfolio covering apremilast and related PDE4 inhibitors.
- Patent landscape analysis reports, 2010–2023, various IP analytics firms.
[End of Article]
More… ↓
⤷ Start Trial
|
